Clinical Trial Update: Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients [Phase 2, Phase 3]

View source ↗

Summary

The phase 2/3 trial of a Modified Melanoma Vaccine for high-risk HLA-A2+ melanoma and metastatic melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Modified melanoma vaccine

Snippet

Sponsor: Hadassah Medical Organization | Conditions: High Risk HLA-A2+ Melanoma, Metastatic Disease | Phase 2, Phase 3 | Status: WITHDRAWN